Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pablo Lavarello, Sebastián Sztulwark, Matías Mancini & Santiago Juncal. (2023) Creative imitation in late industrializing countries: the case of biopharmaceutics in South Korea and India. Innovation and Development 13:1, pages 133-152.
Read now
Read now
Lars Holger Ehlers, Morten B. Jensen & Henrik Schack. (2022) Competitive tenders on analogue hospital pharmaceuticals in Denmark 2017–2020. Journal of Pharmaceutical Policy and Practice 15:1.
Read now
Read now
Hemlata Chhabra, Morgane C Mouslim, Smita Kashiramka & Anurag S Rathore. (2022) Dynamics of biosimilar uptake in emerging markets. Expert Opinion on Biological Therapy 22:6, pages 679-688.
Read now
Read now
Steven Simoens & Raymond Cheung. (2020) Tendering and biosimilars: what role for value-added services?. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Articles from other publishers (24)
Fernando Antoñanzas, Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas. (2023) Tenders for generics and biosimilars: a challenging purchasing policy. The European Journal of Health Economics 24:4, pages 485-487.
Crossref
Crossref
Liese Barbier, Yannick Vandenplas, Niels Boone, Isabelle Huys, Rob Janknegt & Arnold G Vulto. (2022) How to select a best-value biological medicine? A practical model to support hospital pharmacists. American Journal of Health-System Pharmacy 79:22, pages 2001-2011.
Crossref
Crossref
Alan Menter, Stanley Cohen, Jonathan Kay, Vibeke Strand, Alice Gottlieb, Stephen Hanauer, Sravan Kumar Eduru, Susanne Buschke, Benjamin Lang, Karl-Heinz Liesenfeld, Jennifer Schaible & Dorothy McCabe. (2022) Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. American Journal of Clinical Dermatology 23:5, pages 719-728.
Crossref
Crossref
Stephen Hanauer, Bernd Liedert, Sigrid Balser, Ekkehard Brockstedt, Viktoria Moschetti & Stefan Schreiber. (2021) Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology 6:10, pages 816-825.
Crossref
Crossref
Lina Klitgaard Larsen, Emilie Middelbo Outzen, Parisa Gazerani & Hanne Plet. (2019) Complexity of Drug Substitutions Caused by Drug Tenders: A Mixed-Methods Study in Denmark. Hospital Pharmacy 56:4, pages 314-320.
Crossref
Crossref
Sundus Shukar, Fatima Zahoor, Khezar Hayat, Amna Saeed, Ali Hassan Gillani, Sumaira Omer, Shuchen Hu, Zaheer-Ud-Din Babar, Yu Fang & Caijun Yang. (2021) Drug Shortage: Causes, Impact, and Mitigation Strategies. Frontiers in Pharmacology 12.
Crossref
Crossref
Jerome Goldschmidt & Vladimir Hanes. (2020) The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab. Oncology and Therapy 9:1, pages 213-223.
Crossref
Crossref
Liese Barbier, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto & Isabelle Huys. (2021) Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals 14:6, pages 499.
Crossref
Crossref
Tarryn Thaver, Neelaveni Padayachee & Varsha Bangalee. (2021) A comparison study between public and private healthcare sector medicine prices in South Africa. Journal of Pharmaceutical Health Services Research 12:2, pages 194-205.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2021) Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Avi Cherla, Natasha Howard & Elias Mossialos. (2020) The ‘Netflix plus model’: can subscription financing improve access to medicines in low- and middle-income countries?. Health Economics, Policy and Law 16:2, pages 113-123.
Crossref
Crossref
Iqbal Ramzan. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
1
16
.
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G. Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert Selke, Isabelle Huys & Steven Simoens. (2020) Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals 13:10, pages 324.
Crossref
Crossref
Joshua F. Baker, Charles E. Leonard, Vincent Lo ReIIIIII, Michael H. Weisman, Michael D. George & Jonathan Kay. (2020) Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis & Rheumatology 72:7, pages 1067-1071.
Crossref
Crossref
Deborah Gleeson, Joel Lexchin, Ronald Labonté, Belinda Townsend, Marc-André Gagnon, Jillian Kohler, Lisa Forman & Kenneth C. Shadlen. (2019) Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts. Globalization and Health 15:S1.
Crossref
Crossref
Sandra Cuellar, Ali McBride & Patrick Medina. (2019) Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. American Journal of Health-System Pharmacy 76:21, pages 1725-1738.
Crossref
Crossref
Hope S Rugo, Robert M Rifkin, Paul Declerck, Angel H Bair & Geraint Morgan. (2019) Demystifying biosimilars: development, regulation and clinical use. Future Oncology 15:7, pages 777-790.
Crossref
Crossref
Joo Hanne Poulsen, Rikke Mie Rishøj, Hanne Fischer, Trine Kart, Lotte Stig Nørgaard, Christian Sevel, Peter Dieckmann & Marianne Hald Clemmensen. (2019) Drug change: ‘a hassle like no other’. An in-depth investigation using the Danish patient safety database and focus group interviews with Danish hospital personnel. Therapeutic Advances in Drug Safety 10, pages 204209861985999.
Crossref
Crossref
Darija Kuruc Poje. 2019. Pharmaceutical Supply Chains - Medicines Shortages. Pharmaceutical Supply Chains - Medicines Shortages
155
162
.
Yazed S. Alruthia, Monira Alwhaibi, Mashal F. Alotaibi, Shatha A. Asiri, Bushra M. Alghamdi, Ghadah S. Almuaythir, Wejdan R. Alsharif, Hala H. Alrasheed, Yahya A. Alswayeh, Abdulaziz J. Alotaibi, Mohammad Almeshal, Saleh N. Aldekhail, Abdulrahman Alhusaini, Sulaiman A. Alrashed, Ali M. Alrumaih, Mohammed A. Dahhas, Mohammed A. Alghamdi, Mohammad S. Aleheidib, Mohamed H. Alhaidari, Jameel A. Alharbi & Aws Alshamsan. (2018) Drug shortages in Saudi Arabia: Root causes and recommendations. Saudi Pharmaceutical Journal 26:7, pages 947-951.
Crossref
Crossref
Steven Janvier, Bart De Spiegeleer, Celine Vanhee & Eric Deconinck. (2018) Falsification of biotechnology drugs: current dangers and/or future disasters?. Journal of Pharmaceutical and Biomedical Analysis 161, pages 175-191.
Crossref
Crossref
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian & Karol Sikora. (2018) Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. The Oncologist 23:10, pages 1188-1198.
Crossref
Crossref
Don Husereau, Brian Feagan & Carl Selya-Hammer. (2018) Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. Applied Health Economics and Health Policy 16:3, pages 279-288.
Crossref
Crossref
Corrado Blandizzi, Mauro Galeazzi & Guido Valesini. (2018) Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges. Pharmacological Research 128, pages 306-314.
Crossref
Crossref